Mercer University — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$27,092	8
2024	Research	$99,850	24
2023	Research	$97,819	31
2021	Research	$175,886	3
2020	Research	$92,424	31
2019	Research	$4,043	2

Breakdown

Who paid Research payments · program years 2019–2025

Merck Sharp & Dohme Corporation $268,311 34 payments
ViiV Healthcare Company $180,019 53 payments
GlaxoSmithKline, LLC. $48,785 12 payments

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $233,344 13 payments
PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $65,753 17 payments
A Phase Iiib, Randomized, Multicenter, Parallel-Group, Non-Inferiority $58,721 9 payments
A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $41,195 12 payments
A Phase 3B, Multicenter, Single-Arm, Open-Label Study Evaluating the E $38,208 9 payments
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $29,689 7 payments
A Phase 3B, Open Label, Randomized, Standard-Of-Care Control Arm, Mult $10,577 3 payments
A Phase Iib, Multicenter, Open-Label, Rollover Study Evaluating the Ef $9,491 10 payments
A Phase 3, Randomized, Active-Controlled, Double-blind Clinical Study to Evaluate a Switch to Doravirine,Islatravir DOR,ISL Once-Daily in Participants With HIV-1 Virologically Suppressed on Bictegravir,Emtricitabine,Tenofovir Alafenamide BIC,FTC,TAF $5,277 14 payments
A Phase 3B, Open Label, Randomized, Standard-Of-Care Control Arm, Mult $3,420 4 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.